April 18, 2022
Article
PrEP use has been associated with lowering HIV infections worldwide, however use of the treatment alone is not sufficient to prevent HIV from spreading.
April 15, 2022
Cabotegravir is the only current HIV-1 PrEP medication that does need to be taken daily.
April 01, 2022
Video
A panel of experts discuss the role of PrEP in HIV prevention with a focus on current and newly approved options.
March 02, 2022
PrEP involves taking emtricitabine/tenofovir (Truvada or Descovy) to prevent high-risk individuals from contracting HIV.
February 03, 2022
Effective pre-exposure prophylaxis limits the additional price that payers should be willing to pay for the pre-exposure prophylaxis, investigators say.
January 25, 2022
These findings suggest people with indications for PrEP may confront an access barrier if they live in a state that restricts scope of practice, according to the study.
January 14, 2022
Cabotegravir (Apretude) is indicated for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1 infection.
December 10, 2021
The long-acting antiretroviral therapy is intended to replace antiretroviral regimens for individuals who are virologically suppressed.
In this video, Dr. Sherman recommends strategies for solving drug therapy related problems common to long-acting antiretroviral agents, such as missed doses, adverse drug reactions and drug–drug interactions.
December 09, 2021
In this video, Dr. Sherman explains the recent data surrounding the right candidates for long-acting cabotegravir for HIV prevention.
